ClinicalTrials.gg
CompletedNCT00641914STARTUpdated Mar 25, 2009

Inhaled Steroid Treatment as Regular Therapy in Early Asthma

A Phase 4 interventional study of budesonide and Placebo in Asthma, sponsored by AstraZeneca. Completed. Open to participants aged 6 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-03-25.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
6,800
Allocation
Randomized
Ages
6 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Planned enrollment
2nd of 108
6,800 · median 124
Started
1996
the only one that year
Phase 4
33 of 110
3 open now
Registered
39th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 2nd largest by planned enrollment of the 108 interventional ones that give a count, is the only one that started in 1996, is one of 33 in phase 4, and was the 39th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

A study of the effect of the early treatment with Pulmicort of newly diagnosed asthma. Patients will receive either Pulmicort or a non-active treatment for three years. Neither patients or investigators will be aware of the treatment received. After three years of treatment all patients will receive Pulmicort for 2 further years.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Pulmicort
  • budesonide
04

Who can participate

Ages eligible
6 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged between 6 and 60 years
  • diagnosed with asthma within 2 years of starting the study
  • Ability to use a Turbuhaler

Exclusion criteria

Exclusion Criteria:

  • Symptoms indicating asthma (e.g. wheezing) for more than two years prior to starting the study
  • A history of the use of treatments like Pulmicort for more than 30 days per year in the two years before starting the study
  • Regular daily treatment for asthma for more than two years before starting the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
6,800 participants (estimated)

Study arms

  • Experimental
    1

    Drug: budesonide

  • Placebo comparator
    2

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Severe asthma related events (SARE) (part A); post-bronchodilator FEV1 % of predicted normal (part B)

    Time frame: At week 6 and12, and every 3 months thereafter

Secondary outcomes

  1. Pre-bronchodilator FEV1 % of predicted normal

    Time frame: At week 6 and12, and every 3 months thereafter

  2. HE: Asthma related events and health care utilisation, and symptom free days (SFD)

    Time frame: At week 6 and12, and every 3 months thereafter

  3. Post-bronchodilator FVC % of predicted

    Time frame: At week 6 and12, and every 3 months thereafter

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009 Jan 1;179(1):19-24. doi: 10.1164/rccm.200807-1126OC. Epub 2008 Oct 31. Erratum In: Am J Respir Crit Care Med. 2010 Oct 1;182(7):983-4. PubMed 18990678 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1996, a primary completion of Feb 2003 and a completion of Feb 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 24, 2008
Start
Oct 1996
Primary completionActual
Feb 2003
CompletionActual
Feb 2003
Last update
Mar 25, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00641914
Lead sponsor
AstraZeneca
First posted
Mar 24, 2008
Start date
Oct 1996
Primary completion
Feb 2003
Completion
Feb 2003
Last update
Mar 25, 2009

Study contacts

Romain Pauwels
study chair · Steering Committee Chairman
William Busse
study chair · Steering Committee Chairman
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion